company background image
BAJAJHCARE logo

Bajaj HealthCare NSEI:BAJAJHCARE Stock Report

Last Price

₹391.50

Market Cap

₹12.4b

7D

0.1%

1Y

3.4%

Updated

24 Nov, 2024

Data

Company Financials

Bajaj HealthCare Limited

NSEI:BAJAJHCARE Stock Report

Market Cap: ₹12.4b

BAJAJHCARE Stock Overview

A pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. More details

BAJAJHCARE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends2/6

Bajaj HealthCare Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bajaj HealthCare
Historical stock prices
Current Share Price₹391.50
52 Week High₹428.50
52 Week Low₹263.30
Beta0.58
11 Month Change15.01%
3 Month Change-4.56%
1 Year Change3.42%
33 Year Change7.67%
5 Year Changen/a
Change since IPO7.87%

Recent News & Updates

Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00

Sep 12
Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00

Recent updates

Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00

Sep 12
Bajaj HealthCare's (NSE:BAJAJHCARE) Dividend Will Be ₹1.00

Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Jul 12
Bajaj HealthCare Limited (NSE:BAJAJHCARE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Bajaj HealthCare (NSE:BAJAJHCARE) Has Announced That Its Dividend Will Be Reduced To ₹1.00

Sep 10
Bajaj HealthCare (NSE:BAJAJHCARE) Has Announced That Its Dividend Will Be Reduced To ₹1.00

We Think That There Are More Issues For Bajaj HealthCare (NSE:BAJAJHCARE) Than Just Sluggish Earnings

Nov 19
We Think That There Are More Issues For Bajaj HealthCare (NSE:BAJAJHCARE) Than Just Sluggish Earnings

Bajaj HealthCare Limited (NSE:BAJAJHCARE) Soars 30% But It's A Story Of Risk Vs Reward

Jan 17
Bajaj HealthCare Limited (NSE:BAJAJHCARE) Soars 30% But It's A Story Of Risk Vs Reward

Shareholder Returns

BAJAJHCAREIN PharmaceuticalsIN Market
7D0.1%0.5%0.5%
1Y3.4%42.5%27.5%

Return vs Industry: BAJAJHCARE underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.

Return vs Market: BAJAJHCARE underperformed the Indian Market which returned 27.5% over the past year.

Price Volatility

Is BAJAJHCARE's price volatile compared to industry and market?
BAJAJHCARE volatility
BAJAJHCARE Average Weekly Movement5.6%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: BAJAJHCARE has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: BAJAJHCARE's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19931,049Sajankumar Bajajwww.bajajhealth.com

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide).

Bajaj HealthCare Limited Fundamentals Summary

How do Bajaj HealthCare's earnings and revenue compare to its market cap?
BAJAJHCARE fundamental statistics
Market cap₹12.36b
Earnings (TTM)-₹133.27m
Revenue (TTM)₹4.76b

2.6x

P/S Ratio

-92.8x

P/E Ratio

Is BAJAJHCARE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BAJAJHCARE income statement (TTM)
Revenue₹4.76b
Cost of Revenue₹2.45b
Gross Profit₹2.31b
Other Expenses₹2.44b
Earnings-₹133.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.22
Gross Margin48.43%
Net Profit Margin-2.80%
Debt/Equity Ratio119.6%

How did BAJAJHCARE perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

-19%

Payout Ratio